<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>205(5)</volume><submitter>Tajima M</submitter><pubmed_abstract>We propose a novel role for interleukin (IL) 6 in inducing rapid spontaneous proliferation (SP) of naive CD8(+) T cells, which is a crucial step in the differentiation of colitogenic CD8(+) T cells. Homeostasis of T cells is regulated by two distinct modes of cell proliferation: major histocompatibility complex/antigen-driven rapid SP and IL-7/IL-15-dependent slow homeostatic proliferation. Using our novel model of CD8(+) T cell-dependent colitis, we found that SP of naive CD8(+) T cells is essential for inducing pathogenic cytokine-producing effector T cells. The rapid SP was predominantly induced in mesenteric lymph nodes (LNs) but not in peripheral LNs under the influence of intestinal flora and IL-6. Indeed, this SP was markedly inhibited by treatment with anti-IL-6 receptor monoclonal antibody (IL-6R mAb) or antibiotic-induced flora depletion, but not by anti-IL-7R mAb and/or in IL-15-deficient conditions. Concomitantly with the inhibition of SP, anti-IL-6R mAb significantly inhibited the induction of CD8(+) T cell-dependent autoimmune colitis. Notably, the transfer of naive CD8(+) T cells derived from IL-17(-/-) mice did not induce autoimmune colitis. Thus, we conclude that IL-6 signaling is crucial for SP under lymphopenic conditions, which subsequently caused severe IL-17-producing CD8(+) T cell-mediated autoimmune colitis. We suggest that anti-IL-6R mAb may become a promising strategy for the therapy of colitis.</pubmed_abstract><journal>The Journal of experimental medicine</journal><pagination>1019-27</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2373835</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells.</pubmed_title><pmcid>PMC2373835</pmcid><pubmed_authors>Noguchi D</pubmed_authors><pubmed_authors>Ishigame H</pubmed_authors><pubmed_authors>Tajima M</pubmed_authors><pubmed_authors>Chamoto K</pubmed_authors><pubmed_authors>Fugo K</pubmed_authors><pubmed_authors>Kitamura H</pubmed_authors><pubmed_authors>Iwakura Y</pubmed_authors><pubmed_authors>Wakita D</pubmed_authors><pubmed_authors>Nishimura T</pubmed_authors><pubmed_authors>Yue Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells.</name><description>We propose a novel role for interleukin (IL) 6 in inducing rapid spontaneous proliferation (SP) of naive CD8(+) T cells, which is a crucial step in the differentiation of colitogenic CD8(+) T cells. Homeostasis of T cells is regulated by two distinct modes of cell proliferation: major histocompatibility complex/antigen-driven rapid SP and IL-7/IL-15-dependent slow homeostatic proliferation. Using our novel model of CD8(+) T cell-dependent colitis, we found that SP of naive CD8(+) T cells is essential for inducing pathogenic cytokine-producing effector T cells. The rapid SP was predominantly induced in mesenteric lymph nodes (LNs) but not in peripheral LNs under the influence of intestinal flora and IL-6. Indeed, this SP was markedly inhibited by treatment with anti-IL-6 receptor monoclonal antibody (IL-6R mAb) or antibiotic-induced flora depletion, but not by anti-IL-7R mAb and/or in IL-15-deficient conditions. Concomitantly with the inhibition of SP, anti-IL-6R mAb significantly inhibited the induction of CD8(+) T cell-dependent autoimmune colitis. Notably, the transfer of naive CD8(+) T cells derived from IL-17(-/-) mice did not induce autoimmune colitis. Thus, we conclude that IL-6 signaling is crucial for SP under lymphopenic conditions, which subsequently caused severe IL-17-producing CD8(+) T cell-mediated autoimmune colitis. We suggest that anti-IL-6R mAb may become a promising strategy for the therapy of colitis.</description><dates><release>2008-01-01T00:00:00Z</release><publication>2008 May</publication><modification>2026-03-16T16:21:23.221Z</modification><creation>2025-08-30T03:09:46.766Z</creation></dates><accession>S-EPMC2373835</accession><cross_references><pubmed>18426983</pubmed><doi>10.1084/jem.20071133</doi></cross_references></HashMap>